Preventice Solutions

Performance Indicators

In 2020 revenue of Preventice made $158 million that approximately for 30% exceeds an indicator of year prescription.

History

2021: Boston Scientific купила Preventice Solutions

At the end of January, 2021 Boston Scientific purchased Preventice Solutions, the developer of mobile solutions for control of the state of health and services of remote monitoring for patients with cardiac arrhythmia. The solutions Preventice Solutions include the PatientCare platform and family of the BodyGuardian monitors.

The BodyGuardian monitors from Preventice use completely integrated cloud platform using AI algorithms which should improve diagnostics and results of treatment. The latest BodyGuardian Mini Plus system includes several options of electrodes for the best assessment of a rhythm and also is waterproof and can be used in all modalities of short-term and long-term monitoring.

Boston Scientific purchased Preventice Solutions

For the conclusion of the transaction of Boston Scientific company will pay advance payment in the amount of $925 million, and at achievement of certain results - $300 million more. This company is an investor of Preventice since 2015 and already owns 22% of stocks. Boston Scientific expects that its share in capital stock will allow it to pay only $720 million after closing of the transaction.

This acquisition will become a point of support of Boston Scientific in quickly developing sector of an out-patient electrocardiography, will add our portfolio of the implanted cardiomonitors and will become an important component of our strategy in diagnostics and treatment of diseases of heart, - the senior vice president and the president of Boston Scientific Scott Olson noted in the press release.

Olson added that technologies and experience of Preventice will allow Boston Scientific to take quickly new, "very attractive markets". It is expected that the deal will be closed to the middle of 2021.^[1]

Notes